CVRx announces new CPT® Category I codes for Barostim
CVRx, Inc. (NASDAQ: CVRX) announced that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (Barostim) to treat heart failure symptoms. This decision, led by the Society for Vascular Surgery (SVS) and supported by the American College of Cardiology (ACC), will facilitate reimbursement for healthcare providers performing Barostim procedures and enable broader patient access.
The new codes are expected to be implemented on January 1, 2026. Until then, U.S. hospitals and physicians should continue using existing Category III codes. CVRx CEO Kevin Hykes stated that this Category I code designation represents an important milestone for the company and demonstrates the increased adoption, safety, and effectiveness of Barostim as a treatment option for heart failure patients.
CVRx, Inc. (NASDAQ: CVRX) ha annunciato che il Comitato Editoriale CPT® dell'American Medical Association (AMA) ha accettato nuovi codici di Categoria I della Current Procedural Terminology (CPT) per la terapia di attivazione baroreflex (Barostim) per trattare i sintomi di insufficienza cardiaca. Questa decisione, guidata dalla Società di Chirurgia Vascolare (SVS) e supportata dal Collegio Americano di Cardiologia (ACC), faciliterà il rimborso per i fornitori di assistenza sanitaria che eseguono procedure di Barostim e consentirà un accesso più ampio ai pazienti.
I nuovi codici dovrebbero essere implementati il 1 gennaio 2026. Fino ad allora, ospedali e medici statunitensi dovrebbero continuare a utilizzare i codici esistenti di Categoria III. Kevin Hykes, CEO di CVRx, ha dichiarato che questa designazione di codice di Categoria I rappresenta una pietra miliare importante per l'azienda e dimostra l'aumento dell'adozione, della sicurezza e dell'efficacia di Barostim come opzione di trattamento per i pazienti con insufficienza cardiaca.
CVRx, Inc. (NASDAQ: CVRX) anunció que el Panel Editorial CPT® de la Asociación Médica Americana (AMA) ha aceptado nuevos códigos de la Categoría I de la Terminología de Procedimientos Actuales (CPT) para la terapia de activación baroreflex (Barostim) para tratar los síntomas de la insuficiencia cardíaca. Esta decisión, liderada por la Sociedad de Cirugía Vascular (SVS) y apoyada por el Colegio Americano de Cardiología (ACC), facilitará el reembolso para los proveedores de atención médica que realicen procedimientos de Barostim y permitirá un mayor acceso para los pacientes.
Se espera que los nuevos códigos se implementen el 1 de enero de 2026. Hasta entonces, los hospitales y médicos de EE. UU. deben continuar utilizando los códigos de la Categoría III existentes. Kevin Hykes, CEO de CVRx, declaró que esta designación de código de la Categoría I representa un hito importante para la empresa y demuestra la creciente adopción, seguridad y efectividad de Barostim como opción de tratamiento para los pacientes con insuficiencia cardíaca.
CVRx, Inc. (NASDAQ: CVRX)는 미국 의학회(AMA) CPT® 편집 위원회가 심부전 증상을 치료하기 위한 바로리플렉스 활성화 요법(Barostim)에 대한 새로운 현재 절차 용어(CPT) 카테고리 I 코드를 수락했다고 발표했습니다. 이 결정은 혈관 수술 사회(SVS)의 주도 하에 이루어졌으며 미국 심장학회(ACC)의 지원을 받았습니다. 이는 바로스팀 절차를 수행하는 의료 제공자에 대한 상환을 용이하게 하고 환자 접근성을 넓히는 데 도움이 될 것입니다.
새로운 코드는 2026년 1월 1일에 시행될 것으로 예상됩니다. 그때까지 미국의 병원과 의사들은 기존의 카테고리 III 코드를 계속 사용해야 합니다. CVRx의 CEO인 케빈 하이크스는 이 카테고리 I 코드 지정이 회사에 중요한 이정표를 나타내며 심부전 환자에 대한 치료 옵션으로서 Barostim의 채택, 안전성 및 효과가 증가하고 있음을 보여준다고 밝혔습니다.
CVRx, Inc. (NASDAQ: CVRX) a annoncé que le Panel Éditorial CPT® de l'American Medical Association (AMA) a accepté de nouveaux codes de catégorie I de la Terminologie des Procédures Actuelles (CPT) pour la thérapie d'activation baroréflexe (Barostim) afin de traiter les symptômes d'insuffisance cardiaque. Cette décision, menée par la Société de Chirurgie Vasculaire (SVS) et soutenue par le Collège Américain de Cardiologie (ACC), facilitera le remboursement pour les prestataires de soins de santé réalisant des procédures Barostim et permettra un accès plus large des patients.
Les nouveaux codes devraient être mis en œuvre le 1er janvier 2026. D'ici là, les hôpitaux et médecins américains doivent continuer à utiliser les codes de catégorie III existants. Kevin Hykes, PDG de CVRx, a déclaré que cette désignation de code de catégorie I représente une étape importante pour l'entreprise et démontre l'adoption accrue, la sécurité et l'efficacité de Barostim comme option de traitement pour les patients souffrant d'insuffisance cardiaque.
CVRx, Inc. (NASDAQ: CVRX) gab bekannt, dass das CPT®-Editorial-Panel der American Medical Association (AMA) neue Current Procedural Terminology (CPT) Kategorie I-Codes für die Baroreflex-Aktivierungstherapie (Barostim) zur Behandlung von Symptomen der Herzinsuffizienz akzeptiert hat. Diese Entscheidung, geleitet von der Society for Vascular Surgery (SVS) und unterstützt vom American College of Cardiology (ACC), wird die Erstattung für Gesundheitsdienstleister, die Barostim-Verfahren durchführen, erleichtern und den Patienten einen breiteren Zugang ermöglichen.
Die neuen Codes sollen am 1. Januar 2026 implementiert werden. Bis dahin sollten US-Krankenhäuser und Ärzte weiterhin die bestehenden Kategorie III-Codes verwenden. Kevin Hykes, CEO von CVRx, erklärte, dass diese Kategorie I-Code-Zuordnung einen wichtigen Meilenstein für das Unternehmen darstellt und die zunehmende Akzeptanz, Sicherheit und Effektivität von Barostim als Behandlungsoption für Patienten mit Herzinsuffizienz zeigt.
- Acceptance of new CPT Category I codes for Barostim therapy
- Potential for improved reimbursement for healthcare providers
- Expected broader patient access to Barostim treatment
- Recognition of increased adoption, safety, and effectiveness of Barostim
- New codes won't be implemented until January 1, 2026
Insights
The approval of Category I CPT codes for Barostim therapy is a significant development for CVRx. This change from Category III to Category I codes typically indicates a procedure has become more established and widely accepted in medical practice. The implications are substantial:
- Improved reimbursement processes for healthcare providers
- Potential for broader insurance coverage
- Likely increase in patient access to Barostim therapy
The expected implementation date of January 1, 2026, gives CVRx time to prepare for potential increased demand. This development could lead to accelerated adoption of Barostim, potentially driving revenue growth for CVRx in the coming years. However, it's important to note that the full impact may not be immediate and will depend on how quickly insurers and healthcare systems adapt to the new codes.
The support from major medical societies like the Society for Vascular Surgery and the American College of Cardiology adds credibility to the therapy, which could further boost adoption rates. Investors should monitor CVRx's financial reports in the coming quarters for indications of how this change might affect the company's market penetration and revenue trajectory.
MINNEAPOLIS, Oct. 18, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the American Medical Association (AMA) CPT® Editorial Panel has accepted new Current Procedural Terminology (CPT) Category I codes for baroreflex activation therapy (“Barostim”) to treat the symptoms of heart failure.
In response to the increased utilization of Barostim therapy and the strong evidence supporting its clinical outcomes, the AMA CPT Editorial Panel accepted the application for Category I CPT codes. This decision will help further facilitate reimbursement for healthcare providers performing the Barostim procedure and enable broader patient access. This effort was led by the Society for Vascular Surgery (SVS) and supported by the American College of Cardiology (ACC) and others. These codes are expected to be implemented on January 1, 2026. In the interim, U.S. hospitals and physicians performing Barostim procedures should continue to utilize the existing Category III codes.
“We are very pleased that the AMA’s CPT Editorial Panel approved the conversion to Category I codes,” said Kevin Hykes, CEO of CVRx. “The Category I code designation represents an important milestone for the company and is a testament to the increased adoption, safety, and effectiveness of Barostim as an important option for patients suffering from the debilitating symptoms of heart failure. We greatly appreciate the support and guidance that SVS and ACC provided throughout this process.”
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about expected implementation of the Category I CPT code and further facilitation of reimbursement and patient access are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including completion of a formal survey to be conducted by AMA to determine the reimbursement level and the actual impact of the codes on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:
Laura O’Neill
Finn Partners
917.497.2867
laura.oneill@finnpartners.com
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443.213.0501
ir@cvrx.com
FAQ
What new codes did CVRx (CVRX) receive for Barostim therapy?
When will the new CPT Category I codes for Barostim be implemented?
How will the new CPT codes affect Barostim procedures?
Which organizations supported CVRx (CVRX) in obtaining the new CPT codes?
